The first platform combining CRISPR-deactivated Cas9 (dCas9), magnetic beads, and allele-specific qPCR was set up to test the most common EGFR mutations including exon 19 deletion, T790M, and L858R in cfDNA samples of patients with non-small cell lung cancer (NSCLC) (Aalipour et al., 2018). Here, EGFR is linked to non-small cell lung carcinoma.